Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Tick Tock SBM
View:
Post by Pareto8020 on Jun 01, 2021 7:23am

Tick Tock SBM

Wonder if SBM still "anticipates" the achieving the below milestones during the next TWO months?  Remember when they said they were close on the animal deal before Christmas?  Well here we are going into June and still radio silence and no tangible deals, results or anything from Howie yet.  Time to produce or get out of the way - it is embarassing how bad they are at managing this company in everyway possible.   

• Finalize due diligence and agree on terms with new organization in China
• Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
• Secure non-dilutive funding through anticipated collaborations
• Finalize Tinyi agreement
• Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II
Comment by sakinny3 on Jun 01, 2021 9:08am
their list does not include signing new deals for 1067?
Comment by Pandora on Jun 01, 2021 9:14am
Or as Biden would call it -- maybe it's a one horse pony! :-))
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities